首页 > 最新文献

Human Antibodies最新文献

英文 中文
Postural orthostatic tachycardia syndrome-like symptoms following COVID-19 vaccination: An overview of clinical literature. COVID-19疫苗接种后体位性站立性心动过速综合征样症状:临床文献综述
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.3233/HAB-220013
Phu Tv, Thu Thao Tran, Huynh Trung Hao, Nguyen Thi Hien Hau, Nityanand Jain, Aigars Reinis

Background: Postural Orthostatic Tachycardia Syndrome (POTS) is a common condition affecting more than 170 people per 100,000 population. However, POTS following COVID-19 vaccination remains a rare reporting in the medical literature.

Objective: We, herein, summarize and highlight the evidence that has been reported regarding POTS-like symptoms following COVID-19 vaccination.

Methods: We conducted a literature search and summarized the findings in the form of a narrative commentary. All types of publications (case reports/series, original articles, letters to editors, brief communications etc.) in English language were included.

Results: Whilst the exact pathogenetic mechanism behind POTS is yet to elucidated, there has been increasing evidence pointing towards an autoimmune dysfunction. Females were found to be predominantly affected (72%) with age range from 17 years to 52 years. Additionally, it seems that POTS-like symptoms could be triggered after immunization with Pfizer- BioNTech, Moderna, and Oxford-AstraZeneca COVID-19 vaccines. The symptoms typically appear within the first week, depending upon previous exposure to the virus and presence of other systemic conditions. In some patients, the condition is self-resolving. However, in others, non-pharmacological interventions coupled with negative ionotropic medications can be used for symptomatic management of the patients.

Conclusions: Timely diagnosis and proper treatment are quintessential for ensuring early alleviation (and in some cases complete resolution) of symptoms. Furthermore, there may be episodes of relapse. Overall prognosis of the new-onset POTS-like symptoms is difficult to predict based on current literature.

背景:体位性站立性心动过速综合征(POTS)是一种常见病,每10万人中有170多人受到影响。然而,在医学文献中,COVID-19疫苗接种后的POTS仍然是罕见的报道。目的:在此,我们总结和强调已报道的关于COVID-19疫苗接种后pots样症状的证据。方法:我们进行文献检索,并以叙述评论的形式总结研究结果。所有类型的英文出版物(案例报告/系列、原创文章、给编辑的信、简短通讯等)都包括在内。结果:虽然POTS背后的确切发病机制尚未阐明,但越来越多的证据指向自身免疫功能障碍。受影响的主要是女性(72%),年龄范围从17岁到52岁。此外,辉瑞- BioNTech、Moderna和牛津-阿斯利康的新冠疫苗接种后,可能会引发类似pots的症状。症状通常在第一周内出现,这取决于以前与病毒的接触和其他全身性疾病的存在。在一些患者中,这种情况会自行消退。然而,在其他情况下,非药物干预结合负离子化药物可用于患者的症状管理。结论:及时诊断和适当治疗是确保症状早期缓解(在某些情况下完全解决)的关键。此外,还可能出现复发。根据目前的文献,新发pots样症状的总体预后难以预测。
{"title":"Postural orthostatic tachycardia syndrome-like symptoms following COVID-19 vaccination: An overview of clinical literature.","authors":"Phu Tv,&nbsp;Thu Thao Tran,&nbsp;Huynh Trung Hao,&nbsp;Nguyen Thi Hien Hau,&nbsp;Nityanand Jain,&nbsp;Aigars Reinis","doi":"10.3233/HAB-220013","DOIUrl":"https://doi.org/10.3233/HAB-220013","url":null,"abstract":"<p><strong>Background: </strong>Postural Orthostatic Tachycardia Syndrome (POTS) is a common condition affecting more than 170 people per 100,000 population. However, POTS following COVID-19 vaccination remains a rare reporting in the medical literature.</p><p><strong>Objective: </strong>We, herein, summarize and highlight the evidence that has been reported regarding POTS-like symptoms following COVID-19 vaccination.</p><p><strong>Methods: </strong>We conducted a literature search and summarized the findings in the form of a narrative commentary. All types of publications (case reports/series, original articles, letters to editors, brief communications etc.) in English language were included.</p><p><strong>Results: </strong>Whilst the exact pathogenetic mechanism behind POTS is yet to elucidated, there has been increasing evidence pointing towards an autoimmune dysfunction. Females were found to be predominantly affected (72%) with age range from 17 years to 52 years. Additionally, it seems that POTS-like symptoms could be triggered after immunization with Pfizer- BioNTech, Moderna, and Oxford-AstraZeneca COVID-19 vaccines. The symptoms typically appear within the first week, depending upon previous exposure to the virus and presence of other systemic conditions. In some patients, the condition is self-resolving. However, in others, non-pharmacological interventions coupled with negative ionotropic medications can be used for symptomatic management of the patients.</p><p><strong>Conclusions: </strong>Timely diagnosis and proper treatment are quintessential for ensuring early alleviation (and in some cases complete resolution) of symptoms. Furthermore, there may be episodes of relapse. Overall prognosis of the new-onset POTS-like symptoms is difficult to predict based on current literature.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"31 1-2","pages":"9-17"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/f4/hab-31-hab220013.PMC10357168.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9851632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significance of antibody numbering systems in the development of antibody engineering. 抗体编号系统在抗体工程发展中的意义。
Q3 Medicine Pub Date : 2023-01-01 DOI: 10.3233/HAB-230014
Riya Patel, Pratibha Verma, Anil Kumar Nagraj, Akshata Gavade, Om Prakash Sharma, Jaspal Patil

Immunotherapy has become increasingly popular in recent years for treating a variety of diseases including inflammatory, neurological, oncological, and auto-immune disorders. The significant interest in antibody development is due to the high binding affinity and specificity of an antibody against a specific antigen. Recent advances in antibody engineering have provided a different view on how to engineer antibodies in silico for therapeutic and diagnostic applications. In order to improve the clinical utility of therapeutic antibodies, it is of paramount importance to understand the various molecular properties which impact antigen targeting and its potency. In antibody engineering, antibody numbering (AbN) systems play an important role to identify the complementarity determining regions (CDRs) and the framework regions (FR). Hence, it is crucial to accurately define and understand the CDR, FR and the crucial residues of heavy and light chains that aid in the binding of the antibody to the antigenic site. Detailed understanding of amino acids positions are useful for modifying the binding affinity, specificity, physicochemical features, and half-life of an antibody. In this review, we have summarized the different antibody numbering systems that are widely used in antibody engineering and highlighted their significance. Here, we have systematically explored and mentioned the various tools and servers that harness different AbN systems.

近年来,免疫疗法在治疗炎症、神经、肿瘤和自身免疫性疾病等多种疾病方面越来越受欢迎。抗体对特定抗原具有高结合亲和力和特异性,因此抗体开发备受关注。抗体工程的最新进展为如何为治疗和诊断应用进行硅学抗体工程提供了不同的视角。为了提高治疗性抗体的临床实用性,了解影响抗原靶向性及其效力的各种分子特性至关重要。在抗体工程中,抗体编号(ABN)系统在确定互补决定区(CDR)和框架区(FR)方面发挥着重要作用。因此,准确定义和理解 CDR、FR 以及有助于抗体与抗原位点结合的重链和轻链的关键残基至关重要。对氨基酸位置的详细了解有助于改变抗体的结合亲和力、特异性、理化特征和半衰期。在这篇综述中,我们总结了抗体工程中广泛使用的不同抗体编号系统,并强调了它们的重要性。在这里,我们系统地探讨并提到了利用不同抗体编号系统的各种工具和服务器。
{"title":"Significance of antibody numbering systems in the development of antibody engineering.","authors":"Riya Patel, Pratibha Verma, Anil Kumar Nagraj, Akshata Gavade, Om Prakash Sharma, Jaspal Patil","doi":"10.3233/HAB-230014","DOIUrl":"10.3233/HAB-230014","url":null,"abstract":"<p><p>Immunotherapy has become increasingly popular in recent years for treating a variety of diseases including inflammatory, neurological, oncological, and auto-immune disorders. The significant interest in antibody development is due to the high binding affinity and specificity of an antibody against a specific antigen. Recent advances in antibody engineering have provided a different view on how to engineer antibodies in silico for therapeutic and diagnostic applications. In order to improve the clinical utility of therapeutic antibodies, it is of paramount importance to understand the various molecular properties which impact antigen targeting and its potency. In antibody engineering, antibody numbering (AbN) systems play an important role to identify the complementarity determining regions (CDRs) and the framework regions (FR). Hence, it is crucial to accurately define and understand the CDR, FR and the crucial residues of heavy and light chains that aid in the binding of the antibody to the antigenic site. Detailed understanding of amino acids positions are useful for modifying the binding affinity, specificity, physicochemical features, and half-life of an antibody. In this review, we have summarized the different antibody numbering systems that are widely used in antibody engineering and highlighted their significance. Here, we have systematically explored and mentioned the various tools and servers that harness different AbN systems.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":"71-80"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monoclonal antibodies for the treatment of acute lymphocytic leukemia: A literature review. 单克隆抗体治疗急性淋巴细胞白血病的文献综述。
Q3 Medicine Pub Date : 2022-05-27 DOI: 10.3233/hab-211511
Hossein Pourmontaseri, Niloofar Habibzadeh, Sarina Entezari, F. Samadian, Shamim Kiyani, M. Taheri, A. Ahmadi, M. Fallahi, Farzad Sheikhzadeh, Arina Ansari, Amirhossein Tamimi, N. Deravi
BACKGROUNDAcute lymphocytic leukemia (ALL) is a type of blood cancer that is more prevalent in children. Several treatment methods are available for ALL, including chemotherapy, upfront treatment regimens, and pediatric-inspired regimens for adults. Monoclonal antibodies (Mabs) are the novel Food and Drug Administration (FDA) approved remedies for the relapsed/refractory (R/R) adult ALL. In this article, we aimed to review studies that investigated the efficacy and safety of Mabs on ALL.METHODSWe gathered studies through a complete search with all proper related keywords in ISI Web of Science, SID, Scopus, Google Scholar, Science Direct, and PubMed for English language publications up to 2020.RESULTSThe most commonly studied Mabs for ALL therapies are CD-19, CD-20, CD-22, and CD-52. The best results have been reported in the administration of blinatumomab, rituximab, ofatumumab, and inotuzumab with acceptable low side effects.CONCLUSIONAppling personalized approach for achieving higher efficacy is one of the most important aspects of treatment. Moreover, we recommend that the wide use of these Mabs depends on designing further cost-effectiveness trials in this field.
背景:急性淋巴细胞白血病(acute lymphocytic leukemia, ALL)是一种常见于儿童的血癌。目前有几种治疗ALL的方法,包括化疗、前期治疗方案和针对成人的儿科方案。单克隆抗体(mab)是美国食品和药物管理局(FDA)批准的治疗复发/难治性(R/R)成人ALL的新药。在本文中,我们旨在回顾研究单抗治疗ALL的有效性和安全性。方法在ISI Web of Science、SID、Scopus、b谷歌Scholar、Science Direct和PubMed中检索到2020年之前的英文出版物,并对相关关键词进行完整检索。结果针对ALL治疗最常见的单克隆抗体是CD-19、CD-20、CD-22和CD-52。据报道,使用布利纳单抗、利妥昔单抗、奥图单抗和吲哚单抗的效果最好,副作用低。结论应用个性化治疗是提高疗效的重要途径之一。此外,我们建议这些单克隆抗体的广泛使用取决于在该领域设计进一步的成本效益试验。
{"title":"Monoclonal antibodies for the treatment of acute lymphocytic leukemia: A literature review.","authors":"Hossein Pourmontaseri, Niloofar Habibzadeh, Sarina Entezari, F. Samadian, Shamim Kiyani, M. Taheri, A. Ahmadi, M. Fallahi, Farzad Sheikhzadeh, Arina Ansari, Amirhossein Tamimi, N. Deravi","doi":"10.3233/hab-211511","DOIUrl":"https://doi.org/10.3233/hab-211511","url":null,"abstract":"BACKGROUND\u0000Acute lymphocytic leukemia (ALL) is a type of blood cancer that is more prevalent in children. Several treatment methods are available for ALL, including chemotherapy, upfront treatment regimens, and pediatric-inspired regimens for adults. Monoclonal antibodies (Mabs) are the novel Food and Drug Administration (FDA) approved remedies for the relapsed/refractory (R/R) adult ALL. In this article, we aimed to review studies that investigated the efficacy and safety of Mabs on ALL.\u0000\u0000\u0000METHODS\u0000We gathered studies through a complete search with all proper related keywords in ISI Web of Science, SID, Scopus, Google Scholar, Science Direct, and PubMed for English language publications up to 2020.\u0000\u0000\u0000RESULTS\u0000The most commonly studied Mabs for ALL therapies are CD-19, CD-20, CD-22, and CD-52. The best results have been reported in the administration of blinatumomab, rituximab, ofatumumab, and inotuzumab with acceptable low side effects.\u0000\u0000\u0000CONCLUSION\u0000Appling personalized approach for achieving higher efficacy is one of the most important aspects of treatment. Moreover, we recommend that the wide use of these Mabs depends on designing further cost-effectiveness trials in this field.","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47549459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of specific human antibodies against recombinant SARS-CoV-2 receptor binding domain by rapid in-house ELISA. 通过快速内部ELISA评估针对重组严重急性呼吸系统综合征冠状病毒2型受体结合结构域的特异性人类抗体。
Q3 Medicine Pub Date : 2022-03-31 DOI: 10.3233/hab-220003
Nahla Hussein, Esraa Ali, A. El-Hakim, A. Tabll, Asmaa El-Shershaby, Azza Salamony, M. Shaheen, Ibrahim Ali, Mahmoud Elshall, Y. Shahein
BACKGROUNDThe recently emerged SARS-CoV-2 caused a global pandemic since the last two years. The urgent need to control the spread of the virus and rapid application of the suitable health measures raised the importance of available, rapid, and accurate diagnostic approaches.OBJECTIVEThe purpose of this study is to describe a rapid in-house optimized ELISA based on the expression of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein in a prokaryotic system.METHODSWe show the expression of the 30 kDa recombinant SARS-CoV-2 RBD-6×His in five different E. coli strains (at 28∘C using 0.25mM IPTG) including the expression strain E. coli BL21 (DE3) Rosetta Gami. SARS-CoV-2 rRBD-6×His protein was purified, refolded, and used as an antigen coat to assess antibody response in human sera against SARS-CoV-2 infection.RESULTSThe assessment was carried out using a total of 155 human sero-positive and negative SARS-CoV-2 antibodies. The ELISA showed 69.5% sensitivity, 88% specificity, 78.5% agreement, a positive predictive value (PPV) of 92.3%, and a negative predictive value of 56.5%. Moreover, the optical density (OD) values of positive samples significantly correlated with the commercial kit titers.CONCLUSIONSIn conclusion, specific human antibodies against SARS-CoV-2 spike protein were detected by rapid in-house ELISA in sera of human COVID-19-infected patients. The availability of this in-house ELISA protocol would be valuable for various diagnostic and epidemiological applications, particularly in developing countries. Future studies are planned for the use of the generated SARS-CoV-2 rRBD-6×His protein in vaccine development and other diagnostic applications.
背景最近出现的严重急性呼吸系统综合征冠状病毒2型自过去两年以来引发了一场全球大流行。迫切需要控制病毒的传播并迅速采取适当的卫生措施,这提高了可用、快速和准确的诊断方法的重要性。目的本研究的目的是描述一种基于严重急性呼吸系统综合征冠状病毒2型刺突蛋白受体结合域(RBD)在原核系统中表达的快速内部优化ELISA。方法我们显示了30kDa重组严重急性呼吸系统综合征冠状病毒2型RBD-6×His在五种不同的大肠杆菌菌株中的表达(在28℃,使用0.25mM IPTG),包括表达菌株大肠杆菌BL21(DE3)Rosetta Gami。对严重急性呼吸系统综合征冠状病毒2型rRBD-6×His蛋白进行纯化、重折叠,并将其用作抗原外壳,以评估人类血清中对严重急性呼吸道综合征冠状病毒感染的抗体反应。结果使用总共155种人血清阳性和阴性的严重急性呼吸系统综合征冠状病毒2型抗体进行评估。ELISA的敏感性为69.5%,特异性为88%,一致性为78.5%,阳性预测值(PPV)为92.3%,阴性预测值为56.5%。此外,阳性样品的光密度(OD)值与商业试剂盒滴度显著相关。结论通过室内快速酶联免疫吸附试验(ELISA)在人COVID-19感染者血清中检测到了针对SARS-CoV-2刺突蛋白的特异性人抗体。这种内部ELISA方案的可用性对于各种诊断和流行病学应用,特别是在发展中国家,将是有价值的。未来的研究计划将产生的严重急性呼吸系统综合征冠状病毒2 rRBD-6×His蛋白用于疫苗开发和其他诊断应用。
{"title":"Assessment of specific human antibodies against recombinant SARS-CoV-2 receptor binding domain by rapid in-house ELISA.","authors":"Nahla Hussein, Esraa Ali, A. El-Hakim, A. Tabll, Asmaa El-Shershaby, Azza Salamony, M. Shaheen, Ibrahim Ali, Mahmoud Elshall, Y. Shahein","doi":"10.3233/hab-220003","DOIUrl":"https://doi.org/10.3233/hab-220003","url":null,"abstract":"BACKGROUND\u0000The recently emerged SARS-CoV-2 caused a global pandemic since the last two years. The urgent need to control the spread of the virus and rapid application of the suitable health measures raised the importance of available, rapid, and accurate diagnostic approaches.\u0000\u0000\u0000OBJECTIVE\u0000The purpose of this study is to describe a rapid in-house optimized ELISA based on the expression of the receptor binding domain (RBD) of the SARS-CoV-2 spike protein in a prokaryotic system.\u0000\u0000\u0000METHODS\u0000We show the expression of the 30 kDa recombinant SARS-CoV-2 RBD-6×His in five different E. coli strains (at 28∘C using 0.25mM IPTG) including the expression strain E. coli BL21 (DE3) Rosetta Gami. SARS-CoV-2 rRBD-6×His protein was purified, refolded, and used as an antigen coat to assess antibody response in human sera against SARS-CoV-2 infection.\u0000\u0000\u0000RESULTS\u0000The assessment was carried out using a total of 155 human sero-positive and negative SARS-CoV-2 antibodies. The ELISA showed 69.5% sensitivity, 88% specificity, 78.5% agreement, a positive predictive value (PPV) of 92.3%, and a negative predictive value of 56.5%. Moreover, the optical density (OD) values of positive samples significantly correlated with the commercial kit titers.\u0000\u0000\u0000CONCLUSIONS\u0000In conclusion, specific human antibodies against SARS-CoV-2 spike protein were detected by rapid in-house ELISA in sera of human COVID-19-infected patients. The availability of this in-house ELISA protocol would be valuable for various diagnostic and epidemiological applications, particularly in developing countries. Future studies are planned for the use of the generated SARS-CoV-2 rRBD-6×His protein in vaccine development and other diagnostic applications.","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43952429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HLA alleles and haplotype frequencies in Iranian population. 伊朗人群HLA等位基因和单倍型频率。
Q3 Medicine Pub Date : 2022-03-18 DOI: 10.3233/hab-220004
S. Ghafouri-Fard, Bahdar Mahmud Hussen, Sara Pashmforoush, M. Akbari, S. Arsang-Jang, Naghme Nazer, A. Hamidieh, A. Hajifathali, Marcel E. Dinger, A. Sayad, M. O. Dehaghi
BACKGROUNDHLA genotyping is a prerequisite for selection of suitable donors in the process of bone marrow transplantation.METHODSIn the current study, the frequencies of HLA-A, -B, -C and -DRB1 alleles and A-B-C-DRB1 haplotypes were assessed in 855 healthy Iranian persons using a low-resolution sequence specific primer (SSP) kit.RESULTSFrequencies were compared between 11 subpopulations including Armani, Balouch, Bandari, Turk, Turkaman, Arab, Fars, Kurd, Gilaki, Lor and Mazani. In total, 17 HLA-A alleles were detected, one of which (HLA-A*74) was present only among Lors. HLA-A*23 and -A*26 were the most frequent HLA-A alleles among Armanis. HLA-A*23 was also common among Turkamans. HLA-A*11 and -A*26 were most frequent among the Balouch subpopulation. The former allele was also frequent among Bandaris. HLA-A*02 was identified as the most common HLA-A allele among Turk, Arab and Fars subpopulations. HLA-A*30 were strongly enriched among Gilakis. A total of 31 HLA-B alleles were detected across the target population. While all alleles were present among Fars subgroup, Armanis and Turkamans had the lowest degree of diversity among the alleles examined. Moreover, HLA-B*35 and B*49 alleles were strongly enriched among Armanis and Turkamans, respectively. A total of 13 HLA-C alleles were identified across the population, all of which were present in the Fars subpopulation. HLA-C*03 and C*04 were the only HLA-C alleles identified among the Bandari subpopulation. HLA-DRB1*08 was not detected in any subpopulation other than Fars. HLA-DRB1*16 was significantly enriched among Bandaris.CONCLUSIONThese data have practical significance in anthropological studies, disease association investigations and bone marrow transplantation.
背景HLA基因分型是骨髓移植过程中选择合适供体的先决条件。方法在本研究中,使用低分辨率序列特异性引物(SSP)试剂盒评估了855名健康伊朗人的HLA-A、-B、-C和-DRB1等位基因和A-B-C-DRB1单倍型的频率。结果比较了阿玛尼、俾路支、班达里、土耳其人、土库曼人、阿拉伯人、法尔斯人、库尔德人、吉拉基人、洛尔人和马扎尼人等11个亚群的发病率。总共检测到17个HLA-A等位基因,其中一个(HLA-A*74)仅存在于Lors中。HLA-A*23和-A*26是阿曼人中最常见的HLA-A等位基因。HLA-A*23在土库曼人中也很常见。HLA-A*11和-A*26在俾路支亚群中最常见。前一个等位基因在Bandaris中也很常见。HLA-A*02被确定为土耳其人、阿拉伯人和法尔斯人亚群中最常见的HLA-A等位基因。HLA-A*30在吉拉基人中高度富集。在目标人群中总共检测到31个HLA-B等位基因。虽然所有等位基因都存在于Fars亚群中,但在所检测的等位基因中,Armanis和Turkamans的多样性程度最低。此外,HLA-B*35和B*49等位基因在阿曼人和土库曼人中分别富集。在整个人群中共鉴定出13个HLA-C等位基因,所有这些基因都存在于Fars亚群中。HLA-C*03和C*04是班达里亚群中唯一的HLA-C等位基因。在Fars以外的任何亚群中均未检测到HLA-DRB1*08。结论这些数据对人类学研究、疾病相关性研究和骨髓移植具有实际意义。
{"title":"HLA alleles and haplotype frequencies in Iranian population.","authors":"S. Ghafouri-Fard, Bahdar Mahmud Hussen, Sara Pashmforoush, M. Akbari, S. Arsang-Jang, Naghme Nazer, A. Hamidieh, A. Hajifathali, Marcel E. Dinger, A. Sayad, M. O. Dehaghi","doi":"10.3233/hab-220004","DOIUrl":"https://doi.org/10.3233/hab-220004","url":null,"abstract":"BACKGROUND\u0000HLA genotyping is a prerequisite for selection of suitable donors in the process of bone marrow transplantation.\u0000\u0000\u0000METHODS\u0000In the current study, the frequencies of HLA-A, -B, -C and -DRB1 alleles and A-B-C-DRB1 haplotypes were assessed in 855 healthy Iranian persons using a low-resolution sequence specific primer (SSP) kit.\u0000\u0000\u0000RESULTS\u0000Frequencies were compared between 11 subpopulations including Armani, Balouch, Bandari, Turk, Turkaman, Arab, Fars, Kurd, Gilaki, Lor and Mazani. In total, 17 HLA-A alleles were detected, one of which (HLA-A*74) was present only among Lors. HLA-A*23 and -A*26 were the most frequent HLA-A alleles among Armanis. HLA-A*23 was also common among Turkamans. HLA-A*11 and -A*26 were most frequent among the Balouch subpopulation. The former allele was also frequent among Bandaris. HLA-A*02 was identified as the most common HLA-A allele among Turk, Arab and Fars subpopulations. HLA-A*30 were strongly enriched among Gilakis. A total of 31 HLA-B alleles were detected across the target population. While all alleles were present among Fars subgroup, Armanis and Turkamans had the lowest degree of diversity among the alleles examined. Moreover, HLA-B*35 and B*49 alleles were strongly enriched among Armanis and Turkamans, respectively. A total of 13 HLA-C alleles were identified across the population, all of which were present in the Fars subpopulation. HLA-C*03 and C*04 were the only HLA-C alleles identified among the Bandari subpopulation. HLA-DRB1*08 was not detected in any subpopulation other than Fars. HLA-DRB1*16 was significantly enriched among Bandaris.\u0000\u0000\u0000CONCLUSION\u0000These data have practical significance in anthropological studies, disease association investigations and bone marrow transplantation.","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43472601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The seroprevalence of celiac disease in patients with symptoms of irritable bowel syndrome: A cross-sectional study in north of Iran. 肠易激综合征患者乳糜泻的血清患病率:伊朗北部的一项横断面研究
Q3 Medicine Pub Date : 2022-03-16 DOI: 10.3233/hab-211516
F. Joukar, S. Yeganeh, A. Shafaghi, Alireza Mahjoob, Soheil Hassanipour, L. Santacroce, Sara Mavaddati, F. Mansour-Ghanaei
BACKGROUNDCeliac disease (CD) is a common cause of malabsorption that is definitively diagnosed by abnormal bowel biopsy, symptoms and histologic changes to gluten free diet. The symptoms of irritable bowel syndrome (IBS) are common in our community as the majority of people in Guilan, north of Iran, consume rice daily. Also, a number of celiac patients are unknown, and IBS are mistakenly diagnosed.OBJECTIVEThis study aimed to evaluate the prevalence of CD among IBS patients.METHODSA total of 475 consecutive patients with IBS, confirmed by Rome IV, underwent celiac serological tests antitissue transglutaminase antibodies (IgA-tTG, IgG-tTG) after obtaining a written consent form. In case of positive serological tests, biopsy was performed from small intestine after endoscopyRESULTS: Thirty-one (6.53%, 95% CI: 4.55-9.22) patients were positive for celiac serology. Based on Marsh-Oberhuber criteria, out of 9 patients with positive pathology 77.78% (95% CI: 40.19-96.05) had marsh IIIc. In IBS patients cramp (0.009) and stomach fullness (0.021) were two statistically significant IBS symptoms.CONCLUSIONSWe suggest physicians to consider celiac examinations for all patients with IBS symptoms, even for patients with no obvious celiac symptoms.
背景:乳糜泻(CD)是一种常见的吸收不良的原因,通过异常的肠活检、症状和无麸质饮食的组织学改变来确诊。肠易激综合征(IBS)的症状在我们的社区很常见,因为在伊朗北部的吉兰,大多数人每天都吃米饭。此外,许多乳糜泻患者是未知的,肠易激综合征被误诊。目的本研究旨在评估肠易激综合征患者中CD的患病率。方法连续475例经Rome IV确认的IBS患者,在获得书面同意后接受了抗组织转谷氨酰胺酶抗体(IgA-tTG, IgG-tTG)的乳糜泻血清学检测。结果:31例(6.53%,95% CI: 4.55-9.22)患者乳糜泻血清学阳性。根据marsh - oberhuber标准,9例病理阳性患者中77.78% (95% CI: 40.19-96.05)为marsh IIIc。在肠易激综合征患者中,痉挛(0.009)和胃饱(0.021)是两种具有统计学意义的肠易激综合征症状。结论我们建议医生对所有有肠易激综合征症状的患者进行腹腔检查,即使对没有明显腹腔症状的患者也是如此。
{"title":"The seroprevalence of celiac disease in patients with symptoms of irritable bowel syndrome: A cross-sectional study in north of Iran.","authors":"F. Joukar, S. Yeganeh, A. Shafaghi, Alireza Mahjoob, Soheil Hassanipour, L. Santacroce, Sara Mavaddati, F. Mansour-Ghanaei","doi":"10.3233/hab-211516","DOIUrl":"https://doi.org/10.3233/hab-211516","url":null,"abstract":"BACKGROUND\u0000Celiac disease (CD) is a common cause of malabsorption that is definitively diagnosed by abnormal bowel biopsy, symptoms and histologic changes to gluten free diet. The symptoms of irritable bowel syndrome (IBS) are common in our community as the majority of people in Guilan, north of Iran, consume rice daily. Also, a number of celiac patients are unknown, and IBS are mistakenly diagnosed.\u0000\u0000\u0000OBJECTIVE\u0000This study aimed to evaluate the prevalence of CD among IBS patients.\u0000\u0000\u0000METHODS\u0000A total of 475 consecutive patients with IBS, confirmed by Rome IV, underwent celiac serological tests antitissue transglutaminase antibodies (IgA-tTG, IgG-tTG) after obtaining a written consent form. In case of positive serological tests, biopsy was performed from small intestine after endoscopyRESULTS: Thirty-one (6.53%, 95% CI: 4.55-9.22) patients were positive for celiac serology. Based on Marsh-Oberhuber criteria, out of 9 patients with positive pathology 77.78% (95% CI: 40.19-96.05) had marsh IIIc. In IBS patients cramp (0.009) and stomach fullness (0.021) were two statistically significant IBS symptoms.\u0000\u0000\u0000CONCLUSIONS\u0000We suggest physicians to consider celiac examinations for all patients with IBS symptoms, even for patients with no obvious celiac symptoms.","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48933958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Cytometric analysis and clinical features in a Moroccan cohort with severe combined immunodeficiency. 摩洛哥严重联合免疫缺陷队列的细胞分析和临床特征。
Q3 Medicine Pub Date : 2022-01-01 DOI: 10.3233/HAB-211510
Aicha El Allam, Sara El Fakihi, Hicham Tahoune, Karima Sahmoudi, Houria Bousserhane, Youssef Bakri, Naima El Hafidi, Fouad Seghrouchni

Severe combined immunodeficiency (SCID) is a form of primary immunodeficiency disease (PID). It is characterized by a serious abnormality of the cellular and sometimes humoral system due to a deficiency in development of T cells, B cells and/or NK cells. The early diagnosis of SCID improves the prognosis. Typically, the initial consideration of SCID is made based on low lymphocyte counts. Notwithstanding, the heterogeneity of lymphocyte count presentation makes the diagnosis of SCID a significant challenge. The objective of this cross-sectional retrospective study was to analyze the lymphocyte subpopulation counts along with clinical manifestations within a Moroccan cohort diagnosed as SCID compared to children diagnosed with non-PID diseases. Thirty-five SCID confirmed patients were selected in the period between 2008 and 2018 and compared with non-PID patients. Results of peripheral blood T, B, and NK lymphocyte subpopulation counts were measured by flow cytometry for each SCID subtype. As expected, T cell count was less than 300 cells/μL in most patients with SCID (85.5%). Unexpectedly, significantly higher T cell counts were detected in some patients with a confirmed clinical diagnosis and family history of SCID. 5.7% of our SCID Moroccan cohort had T cell numbers in the range between 300 and 500 cells/μL. 8.7% of our SCID Moroccan cohort had T cell numbers higher than 500 cells/μL. Of the SCID subtypes, the proportion of SCID with B cell deficiencies was highly represented in our cohort. 71.4% of Moroccan SCID patients (25 out of 35 patients) were of T-B-subtype. Furthermore, 40% of the patients (14 out of 35 patients) had a T-B-NK+ profile and 31.4% had a T-B-NK- profile (11 out of 35 patients). The most common clinical manifestations observed in our SCID cohort were pneumonia, failure to thrive, candidiasis, diarrhea, bronchitis and urinary tract infections. Our results not only highlight the relatively frequent presence of atypical SCID in the Moroccan population with unexpectedly high T cell numbers, but also describes the incidence pattern of common SCID subtypes in Morocco. Physicians in Morocco may find this local region-specific difference in SCID important for making improved early diagnosis of this disease.

重度联合免疫缺陷(SCID)是原发性免疫缺陷疾病(PID)的一种形式。它的特点是由于T细胞、B细胞和/或NK细胞发育不足而导致细胞和有时体液系统的严重异常。SCID的早期诊断可改善预后。通常,对SCID的初步考虑是基于低淋巴细胞计数。尽管如此,淋巴细胞计数表现的异质性使得SCID的诊断面临重大挑战。本横断面回顾性研究的目的是分析诊断为SCID的摩洛哥队列中与诊断为非pid疾病的儿童相比的淋巴细胞亚群计数和临床表现。在2008年至2018年期间选择35例SCID确诊患者,并与非pid患者进行比较。流式细胞术检测各组SCID亚型外周血T、B、NK淋巴细胞亚群计数。正如预期的那样,大多数SCID患者(85.5%)的T细胞计数小于300个细胞/μL。出乎意料的是,在一些临床确诊和有SCID家族史的患者中检测到明显较高的T细胞计数。5.7%的SCID摩洛哥队列患者T细胞数量在300 - 500细胞/μL之间。8.7%的SCID摩洛哥队列患者T细胞数量高于500细胞/μL。在SCID亚型中,伴有B细胞缺陷的SCID比例在我们的队列中有很高的代表性。71.4%的摩洛哥SCID患者(35例患者中有25例)为t - b亚型。此外,40%的患者(35例患者中有14例)具有T-B-NK+特征,31.4%的患者具有T-B-NK-特征(35例患者中有11例)。在我们的SCID队列中观察到的最常见的临床表现是肺炎、生长不良、念珠菌病、腹泻、支气管炎和尿路感染。我们的研究结果不仅突出了非典型SCID在摩洛哥人群中相对频繁的存在,而且还描述了摩洛哥常见SCID亚型的发病率模式。摩洛哥的医生可能会发现SCID的这种局部区域特异性差异对改善这种疾病的早期诊断很重要。
{"title":"Cytometric analysis and clinical features in a Moroccan cohort with severe combined immunodeficiency.","authors":"Aicha El Allam,&nbsp;Sara El Fakihi,&nbsp;Hicham Tahoune,&nbsp;Karima Sahmoudi,&nbsp;Houria Bousserhane,&nbsp;Youssef Bakri,&nbsp;Naima El Hafidi,&nbsp;Fouad Seghrouchni","doi":"10.3233/HAB-211510","DOIUrl":"https://doi.org/10.3233/HAB-211510","url":null,"abstract":"<p><p>Severe combined immunodeficiency (SCID) is a form of primary immunodeficiency disease (PID). It is characterized by a serious abnormality of the cellular and sometimes humoral system due to a deficiency in development of T cells, B cells and/or NK cells. The early diagnosis of SCID improves the prognosis. Typically, the initial consideration of SCID is made based on low lymphocyte counts. Notwithstanding, the heterogeneity of lymphocyte count presentation makes the diagnosis of SCID a significant challenge. The objective of this cross-sectional retrospective study was to analyze the lymphocyte subpopulation counts along with clinical manifestations within a Moroccan cohort diagnosed as SCID compared to children diagnosed with non-PID diseases. Thirty-five SCID confirmed patients were selected in the period between 2008 and 2018 and compared with non-PID patients. Results of peripheral blood T, B, and NK lymphocyte subpopulation counts were measured by flow cytometry for each SCID subtype. As expected, T cell count was less than 300 cells/μL in most patients with SCID (85.5%). Unexpectedly, significantly higher T cell counts were detected in some patients with a confirmed clinical diagnosis and family history of SCID. 5.7% of our SCID Moroccan cohort had T cell numbers in the range between 300 and 500 cells/μL. 8.7% of our SCID Moroccan cohort had T cell numbers higher than 500 cells/μL. Of the SCID subtypes, the proportion of SCID with B cell deficiencies was highly represented in our cohort. 71.4% of Moroccan SCID patients (25 out of 35 patients) were of T-B-subtype. Furthermore, 40% of the patients (14 out of 35 patients) had a T-B-NK+ profile and 31.4% had a T-B-NK- profile (11 out of 35 patients). The most common clinical manifestations observed in our SCID cohort were pneumonia, failure to thrive, candidiasis, diarrhea, bronchitis and urinary tract infections. Our results not only highlight the relatively frequent presence of atypical SCID in the Moroccan population with unexpectedly high T cell numbers, but also describes the incidence pattern of common SCID subtypes in Morocco. Physicians in Morocco may find this local region-specific difference in SCID important for making improved early diagnosis of this disease.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"30 2","pages":"67-77"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39571348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-invasive monitoring associated with B lymphoma cells in post-transplant lymphoproliferative disorder (PTLD) patients: Systematic review. 移植后淋巴细胞增生性疾病(PTLD)患者B淋巴瘤细胞的无创监测:系统综述
Q3 Medicine Pub Date : 2022-01-01 DOI: 10.3233/HAB-220016
Naser Honar, Iraj Shahramian, Mohammad Hadi Imanieh, Maryam Ataollahi, Masoud Tahani, Shiva Rakhshaninasab, Amin Javadifar

Background: One of the most severe side effects of solid-organ transplantation is posttransplant lymphoproliferative disease (PTLD). People with human immunodeficiency virus infection (HIV), an immunosuppressive disease comparable to HIV, have a higher chance of developing lymphoma when their peripheral blood contains elevated levels of the immunoglobulins kappa and lambda free light chains (FLCs).

Methods: This systematic review's objective was to monitor associated B lymphoma cells in PTLD patients. In order to find relevant studies published between 1/1/2000 and 1/9/2022, two independent researchers conducted searches (MT, AJ). A literature search of English language publications was conducted using MEDLINE through PubMed, EMBASETM through Ovid, the Cochrane Library, and Trip. In addition to Magiran and SID, we searched KoreaMed and LILACS for literature published in other languages. sFLC or PTLD, transplant, or Electrophoresis are terms used in the search strategy.

Results: A total of 174 studies were selected. After analyzing their correspondence with the required criteria, a final review of five studies was conducted. The manuscript presents current findings on the potential benefits of the clinical applicability of sFLCs in PTLD. While the preliminary results appear promising, the only consistent result is that early-onset PTLD is predicted within the first two years after transplant, a biomarker that could be used to diagnose the condition.

Conclusions: Therefore, PTLD has been predicted by using the sFLCs. There have been contradictory results to date. Future research could include assessing the quantity of sFLCs and their quality in transplant recipients. In addition to PTLD and complications after transplantation, sFLCs may provide insight into other diseases. To confirm the validity of sFLCs, more studies are needed.

背景:实体器官移植最严重的副作用之一是移植后淋巴细胞增生性疾病(PTLD)。人类免疫缺陷病毒感染(HIV)是一种类似于HIV的免疫抑制疾病,当患者外周血中免疫球蛋白kappa和游离轻链(FLCs)水平升高时,患者发生淋巴瘤的几率更高。方法:本系统综述的目的是监测PTLD患者的相关B淋巴瘤细胞。为了找到2000年1月1日至2022年1月9日之间发表的相关研究,两位独立研究人员进行了搜索(MT, AJ)。使用PubMed的MEDLINE、Ovid的ememetm、Cochrane图书馆和Trip对英文出版物进行文献检索。除了Magiran和SID,我们还在KoreaMed和LILACS上搜索了其他语言出版的文献。sFLC或PTLD、移植或电泳是搜索策略中使用的术语。结果:共纳入174项研究。在分析了它们与所需标准的对应关系后,对五项研究进行了最后审查。本文介绍了目前关于sFLCs在PTLD临床应用的潜在益处的研究结果。虽然初步结果看起来很有希望,但唯一一致的结果是,早发性PTLD可以在移植后的头两年内预测,这是一种可用于诊断这种疾病的生物标志物。结论:因此,使用sFLCs可以预测PTLD。迄今为止,有一些相互矛盾的结果。未来的研究可能包括评估移植受者体内sFLCs的数量和质量。除了PTLD和移植后的并发症外,sFLCs可能为其他疾病的研究提供线索。为了证实sFLCs的有效性,还需要更多的研究。
{"title":"Non-invasive monitoring associated with B lymphoma cells in post-transplant lymphoproliferative disorder (PTLD) patients: Systematic review.","authors":"Naser Honar,&nbsp;Iraj Shahramian,&nbsp;Mohammad Hadi Imanieh,&nbsp;Maryam Ataollahi,&nbsp;Masoud Tahani,&nbsp;Shiva Rakhshaninasab,&nbsp;Amin Javadifar","doi":"10.3233/HAB-220016","DOIUrl":"https://doi.org/10.3233/HAB-220016","url":null,"abstract":"<p><strong>Background: </strong>One of the most severe side effects of solid-organ transplantation is posttransplant lymphoproliferative disease (PTLD). People with human immunodeficiency virus infection (HIV), an immunosuppressive disease comparable to HIV, have a higher chance of developing lymphoma when their peripheral blood contains elevated levels of the immunoglobulins kappa and lambda free light chains (FLCs).</p><p><strong>Methods: </strong>This systematic review's objective was to monitor associated B lymphoma cells in PTLD patients. In order to find relevant studies published between 1/1/2000 and 1/9/2022, two independent researchers conducted searches (MT, AJ). A literature search of English language publications was conducted using MEDLINE through PubMed, EMBASETM through Ovid, the Cochrane Library, and Trip. In addition to Magiran and SID, we searched KoreaMed and LILACS for literature published in other languages. sFLC or PTLD, transplant, or Electrophoresis are terms used in the search strategy.</p><p><strong>Results: </strong>A total of 174 studies were selected. After analyzing their correspondence with the required criteria, a final review of five studies was conducted. The manuscript presents current findings on the potential benefits of the clinical applicability of sFLCs in PTLD. While the preliminary results appear promising, the only consistent result is that early-onset PTLD is predicted within the first two years after transplant, a biomarker that could be used to diagnose the condition.</p><p><strong>Conclusions: </strong>Therefore, PTLD has been predicted by using the sFLCs. There have been contradictory results to date. Future research could include assessing the quantity of sFLCs and their quality in transplant recipients. In addition to PTLD and complications after transplantation, sFLCs may provide insight into other diseases. To confirm the validity of sFLCs, more studies are needed.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"30 4","pages":"183-194"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9467309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The comparison of IL-17 levels in patients with unstable angina before and after medical treatment. 不稳定型心绞痛患者用药前后IL-17水平的比较
Q3 Medicine Pub Date : 2022-01-01 DOI: 10.3233/HAB-210446
Ahmad Boluri, Hosseinali Khazaei, Narjes Sargolzaei, Hanie Olfat Miri, Bahman Khazaei

Background: Interleukin (IL)-17 plays a central role in orchestrating the cytokine cascade and accelerates atherosclerosis and plaque vulnerability in animal models. However, epidemiological data evaluating the role of IL-17 levels in unstable angina are lacking. The aim of our study is to evaluate and compare the IL-17 levels in unstable angina (UA) cases before and after treatment.

Methods: This cross-sectional study was performed from July to October 2018 in Ali Iben-abitaleb heart center, Zahedan, Iran. 48 patients with UA in the age range of below 50 years entered the study. All demographic, past medical history, physical examination, electrocardiogram (EKG or ECG), and transthoracic echocardiogram (TTE) data were collected. Serum level of IL-17 was measured using enzyme-linked immunosorbent assay (ELISA) method. In all the tests, P< 0.05 was considered as statistically significant. All data analyses were performed using the SPSS 13.0 software (SPSS Inc., Chicago, Illinois, USA).

Results: In this study, 48 UA patients, including 34 women and 16 men with a mean age of 56.60 years were included in the study. The mean serum level of interleukin 17 after treatment (65.13 ± 53.29 pg/dl) was significantly lower than Its level before treatment (94.89 ± 51.25 pg/dL) (P< 0/05).

Conclusion: Our findings point towards a role of inflammation in the form of increased activity of IL-17 in UA patients and thus suggest that IL-17-driven inflammation may play a role in the promotion of clinical instability in patients with coronary artery disease.

背景:在动物模型中,白细胞介素(IL)-17在协调细胞因子级联和加速动脉粥样硬化和斑块易损性中起核心作用。然而,评估IL-17水平在不稳定型心绞痛中的作用的流行病学数据缺乏。本研究的目的是评估和比较不稳定型心绞痛(UA)患者治疗前后的IL-17水平。方法:本横断面研究于2018年7月至10月在伊朗扎黑丹Ali Iben-abitaleb心脏中心进行,纳入48例年龄在50岁以下的UA患者。收集所有人口统计、既往病史、体格检查、心电图(EKG或ECG)和经胸超声心动图(TTE)数据。采用酶联免疫吸附法(ELISA)检测血清IL-17水平。所有检验均以P< 0.05为差异有统计学意义。所有数据分析使用SPSS 13.0软件(SPSS Inc., Chicago, Illinois, USA)进行。结果:本研究纳入48例UA患者,其中女性34例,男性16例,平均年龄56.60岁。治疗后血清白细胞介素17的平均水平(65.13±53.29 pg/dl)显著低于治疗前(94.89±51.25 pg/dl) (P< 0/05)。结论:我们的研究结果指出炎症在UA患者中以IL-17活性增加的形式发挥作用,因此表明IL-17驱动的炎症可能在冠状动脉疾病患者的临床不稳定中起促进作用。
{"title":"The comparison of IL-17 levels in patients with unstable angina before and after medical treatment.","authors":"Ahmad Boluri,&nbsp;Hosseinali Khazaei,&nbsp;Narjes Sargolzaei,&nbsp;Hanie Olfat Miri,&nbsp;Bahman Khazaei","doi":"10.3233/HAB-210446","DOIUrl":"https://doi.org/10.3233/HAB-210446","url":null,"abstract":"<p><strong>Background: </strong>Interleukin (IL)-17 plays a central role in orchestrating the cytokine cascade and accelerates atherosclerosis and plaque vulnerability in animal models. However, epidemiological data evaluating the role of IL-17 levels in unstable angina are lacking. The aim of our study is to evaluate and compare the IL-17 levels in unstable angina (UA) cases before and after treatment.</p><p><strong>Methods: </strong>This cross-sectional study was performed from July to October 2018 in Ali Iben-abitaleb heart center, Zahedan, Iran. 48 patients with UA in the age range of below 50 years entered the study. All demographic, past medical history, physical examination, electrocardiogram (EKG or ECG), and transthoracic echocardiogram (TTE) data were collected. Serum level of IL-17 was measured using enzyme-linked immunosorbent assay (ELISA) method. In all the tests, P< 0.05 was considered as statistically significant. All data analyses were performed using the SPSS 13.0 software (SPSS Inc., Chicago, Illinois, USA).</p><p><strong>Results: </strong>In this study, 48 UA patients, including 34 women and 16 men with a mean age of 56.60 years were included in the study. The mean serum level of interleukin 17 after treatment (65.13 ± 53.29 pg/dl) was significantly lower than Its level before treatment (94.89 ± 51.25 pg/dL) (P< 0/05).</p><p><strong>Conclusion: </strong>Our findings point towards a role of inflammation in the form of increased activity of IL-17 in UA patients and thus suggest that IL-17-driven inflammation may play a role in the promotion of clinical instability in patients with coronary artery disease.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"30 1","pages":"25-29"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-210446","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39065846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of cancer prevention effect of exercise. 运动防癌效果的评估。
Q3 Medicine Pub Date : 2022-01-01 DOI: 10.3233/HAB-210454
Reza Vafaee, Mostafa Rezaei Tavirani, Sina Rezaei Tavirani, Mohammadreza Razzaghi

There are many documents about benefits of exercise on human health. However, evidences indicate to positive effect of exercise on disease prevention, understanding of many aspects of this mechanism need more investigations. Determination of critical genes which effect human health.GSE156249 including 12 gene expression profiles of healthy individual biopsy from vastus lateralis muscle before and after 12-week combined exercise training intervention were extracted from gene expression omnibus (GEO) database. The significant DEGs were included in interactome unit by Cytoscape software and STRING database. The network was analyzed to find the central nodes subnetwork clusters. The nodes of prominent cluster were assessed via gene ontology by using ClueGO. Number of 8 significant DEGs and 100 first neighbors analyzed via network analysis. The network includes 2 clusters and COL3A1, BGN, and LOX were determined as central DEGs. The critical DEGs were involved in cancer prevention process.

关于运动对人体健康的好处有很多文献。然而,有证据表明运动对疾病的预防有积极作用,对这一机制的许多方面的理解还需要进一步的研究。影响人体健康的关键基因的测定。从基因表达综合数据库(GEO)中提取了12周联合运动训练干预前后健康个体股外侧肌活检组织的12个基因表达谱GSE156249。通过Cytoscape软件和STRING数据库将具有显著意义的deg纳入互作组单元。对网络进行分析,找出中心节点子网簇。利用ClueGO对突出聚类的节点进行基因本体评估。通过网络分析分析了8个显著deg和100个第一邻居的数量。该网络包括2个集群,COL3A1、BGN和LOX被确定为中心deg。关键deg参与癌症预防过程。
{"title":"Assessment of cancer prevention effect of exercise.","authors":"Reza Vafaee,&nbsp;Mostafa Rezaei Tavirani,&nbsp;Sina Rezaei Tavirani,&nbsp;Mohammadreza Razzaghi","doi":"10.3233/HAB-210454","DOIUrl":"https://doi.org/10.3233/HAB-210454","url":null,"abstract":"<p><p>There are many documents about benefits of exercise on human health. However, evidences indicate to positive effect of exercise on disease prevention, understanding of many aspects of this mechanism need more investigations. Determination of critical genes which effect human health.GSE156249 including 12 gene expression profiles of healthy individual biopsy from vastus lateralis muscle before and after 12-week combined exercise training intervention were extracted from gene expression omnibus (GEO) database. The significant DEGs were included in interactome unit by Cytoscape software and STRING database. The network was analyzed to find the central nodes subnetwork clusters. The nodes of prominent cluster were assessed via gene ontology by using ClueGO. Number of 8 significant DEGs and 100 first neighbors analyzed via network analysis. The network includes 2 clusters and COL3A1, BGN, and LOX were determined as central DEGs. The critical DEGs were involved in cancer prevention process.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"30 1","pages":"31-36"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39382436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Antibodies
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1